Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Campbell, Kathryn
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT04884815 / 2020-005266-34: A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease	Recruiting	1/2	82	Europe, Canada, US	UX701, rivunatpagene miziparvovec, Standard of Care (SOC)	Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.	Wilson Disease	03/29	03/34
Portis, Andrea
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Campbell, Kathryn
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT04884815 / 2020-005266-34: A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease	Recruiting	1/2	82	Europe, Canada, US	UX701, rivunatpagene miziparvovec, Standard of Care (SOC)	Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.	Wilson Disease	03/29	03/34
Portis, Andrea
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis	Active, not recruiting	2	180	US, RoW	Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent	Zydus Therapeutics Inc.	Nonalcoholic Steatohepatitis, Fibrosis	09/25	09/25